Elm Grove, WI, April 20, 2021 – IQ-AI, Ltd (publicly traded on the London Stock Exchange as IQAI) will finance a Phase I clinical trial to evaluate the safety and efficacy of Gallium Maltolate (GaM) in the treatment of Glioblastoma Multiforme (GBM). Scheduled to start this summer, the trial will consist of approximately 20 patients and will be conducted at the Medical College of Wisconsin (MCW).